Psoriatic Arthritis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 128 pages report, published by Global Markets Direct

Keywords : Psoriatic Arthritis Therapeutic Products under Development, Key Players in Psoriatic Arthritis Therapeutics, Psoriatic Arthritis Pipeline Overview, Psoriatic Arthritis Pipeline, Psoriatic Arthritis Pipeline Assessment

Report ThumbnailSeptember-2013
Psoriatic Arthritis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Psoriatic Arthritis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. Psoriatic Arthritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psoriatic Arthritis.
- A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriatic Arthritis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Psoriatic Arthritis, H2 2013 9
  • Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Late Stage Products, H2 2013 14
  • Mid Clinical Stage Products, H2 2013 15
  • Early Clinical Stage Products, H2 2013 16
  • Discovery and Pre-Clinical Stage Products, H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 37
  • Assessment by Route of Administration, H2 2013 38
  • Assessment by Stage and Route of Administration, H2 2013 39
  • Assessment by Molecule Type, H2 2013 40
  • Assessment by Stage and Molecule Type, H2 2013 41
  • List of Tables
  • Number of Products Under Development for Psoriatic Arthritis, H2 2013 9
  • Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Development by Companies, H2 2013 (Contd..1) 13
  • Comparative Analysis by Late Stage Development, H2 2013 14
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 16
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
  • Products under Development by Companies, H2 2013 18
  • Products under Development by Companies, H2 2013 (Contd..1) 19
  • Alcon, Inc., H2 2013 20
  • Johnson & Johnson, H2 2013 21
  • Amgen Inc., H2 2013 22
  • Eli Lilly and Company, H2 2013 23
  • Celltrion, Inc., H2 2013 24
  • Biocon Limited, H2 2013 25
  • Pfizer Inc., H2 2013 26
  • UCB Group, H2 2013 27
  • Celgene Corporation, H2 2013 28
  • Biovitrum AB, H2 2013 29
  • Panacea Biotec Limited, H2 2013 30
  • Viropro Inc., H2 2013 31
  • Alder Biopharmaceuticals Inc., H2 2013 32
  • Coronado Biosciences, Inc., H2 2013 33
  • Covagen AG, H2 2013 34
  • Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2013 35
  • Bio Sidus S.A., H2 2013 36
  • Assessment by Monotherapy Products, H2 2013 37
  • Assessment by Stage and Route of Administration, H2 2013 39
  • Assessment by Stage and Molecule Type, H2 2013 41
  • Psoriatic Arthritis Therapeutics - Drug Profile Updates 82
  • Psoriatic Arthritis Therapeutics - Discontinued Products 113
  • Psoriatic Arthritis Therapeutics - Dormant Products 114
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Psoriatic Arthritis Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Psoriatic Arthritis 9
  • Psoriatic Arthritis Therapeutics under Development by Companies 11
  • Late Stage Products 14
  • Comparative Analysis 14
  • Mid Clinical Stage Products 15
  • Comparative Analysis 15
  • Early Clinical Stage Products 16
  • Comparative Analysis 16
  • Discovery and Pre-Clinical Stage Products 17
  • Comparative Analysis 17
  • Psoriatic Arthritis Therapeutics - Products under Development by Companies 18
  • Companies Involved in Psoriatic Arthritis Therapeutics Development 20
  • Alcon, Inc. 20
  • Johnson & Johnson 21
  • Amgen Inc. 22
  • Eli Lilly and Company 23
  • Celltrion, Inc. 24
  • Biocon Limited 25
  • Pfizer Inc. 26
  • UCB Group 27
  • Celgene Corporation 28
  • Biovitrum AB 29
  • Panacea Biotec Limited 30
  • Viropro Inc. 31
  • Alder Biopharmaceuticals Inc. 32
  • Coronado Biosciences, Inc. 33
  • Covagen AG 34
  • Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 35
  • Bio Sidus S.A. 36
  • Psoriatic Arthritis - Therapeutics Assessment 37
  • Assessment by Monotherapy Products 37
  • Assessment by Route of Administration 38
  • Assessment by Molecule Type 40
  • Drug Profiles 42
  • brodalumab - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • ixekizumab - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • tofacitinib - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • apremilast - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • apremilast - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • secukinumab - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • certolizumab pegol - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • ustekinumab - Drug Profile 62
  • Product Description 62
  • Mechanism of Action 62
  • R&D Progress 62
  • clazakizumab - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • TSO - Drug Profile 66
  • Product Description 66
  • Mechanism of Action 66
  • R&D Progress 66
  • infliximab biosimilar - Drug Profile 68
  • Product Description 68
  • Mechanism of Action 68
  • R&D Progress 68
  • adalimumab biosimilar - Drug Profile 70
  • Product Description 70
  • Mechanism of Action 70
  • R&D Progress 70
  • COVA-322 - Drug Profile 71
  • Product Description 71
  • Mechanism of Action 71
  • R&D Progress 71
  • infliximab biosimilar - Drug Profile 72
  • Product Description 72
  • Mechanism of Action 72
  • R&D Progress 72
  • etanercept biosimilar - Drug Profile 73
  • Product Description 73
  • Mechanism of Action 73
  • R&D Progress 73
  • infliximab biosimilar - Drug Profile 74
  • Product Description 74
  • Mechanism of Action 74
  • R&D Progress 74
  • adalimumab biosimilar - Drug Profile 75
  • Product Description 75
  • Mechanism of Action 75
  • R&D Progress 75
  • infliximab biosimilar - Drug Profile 76
  • Product Description 76
  • Mechanism of Action 76
  • R&D Progress 76
  • etanercept biosimilar - Drug Profile 77
  • Product Description 77
  • Mechanism of Action 77
  • R&D Progress 77
  • adalimumab biosimilar - Drug Profile 78
  • Product Description 78
  • Mechanism of Action 78
  • R&D Progress 78
  • adalimumab biosimilar - Drug Profile 79
  • Product Description 79
  • Mechanism of Action 79
  • R&D Progress 79
  • etanercept biosimilar - Drug Profile 80
  • Product Description 80
  • Mechanism of Action 80
  • R&D Progress 80
  • adalimumab biosimilar - Drug Profile 81
  • Product Description 81
  • Mechanism of Action 81
  • R&D Progress 81
  • Psoriatic Arthritis Therapeutics - Drug Profile Updates 82
  • Psoriatic Arthritis Therapeutics - Discontinued Products 113
  • Psoriatic Arthritis Therapeutics - Dormant Products 114
  • Psoriatic Arthritis - Product Development Milestones 115
  • Featured News & Press Releases 115
  • Jul 25, 2013: CHMP Adopts Positive Opinion For Janssen Biologics's Simponi 115
  • Jul 25, 2013: Janssen-Cilag's Stelara Receives CHMP Positive Opinion 116
  • Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima 116
  • Jun 13, 2013: Celgene Presents Data From Phase III Randomized Controlled Study Of Apremilast In Psoriatic Arthritis At EULAR 119
  • Jun 13, 2013: Janssen Announces Publication Of Phase III Study Results Of Stelara In Treatment Of Active Psoriatic Arthritis In Lancet 120
  • Jun 12, 2013: Celgene Announces Positive Phase III Study Results Of Oral Apremilast At EULAR Annual Meeting 122
  • Jun 12, 2013: Amgen And AstraZeneca To Present Data From Phase II Study Of Brodalumab At 2013 EULAR Annual Meeting 123
  • Jun 11, 2013: J&J's Stelara Shows Improvement In Signs And Symptoms Of Psoriatic Arthritis In Phase III Trial 124
  • May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process 125
  • May 06, 2013: Celgene's Apremilast Achieves Statistical Significance For Primary And Major Secondary Endpoints In Fourth Pivotal Phase III Study In Patients With Psoriatic Arthritis 125
  • Appendix 127
  • Methodology 127
  • Coverage 127
  • Secondary Research 127
  • Primary Research 127
  • Expert Panel Validation 127
  • Contact Us 128
  • Disclaimer 128

Please select a license type

Share

Related Products

Global Markets DirectPsoriatic Arthritis - Pipeline Review, H2 2013Product ThumbnailPsoriatic Arthritis - Pipeline Review, H2 2013, Industry ReportProduct #: 113290
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved